Guang-yu J. Liu
270 Dong An Road
Shanghai, 200032, China
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 139 publications
ASO Visual Abstract: Omission of Axillary Surgery in Patients with Negative Axillary Evaluation Integrated with LymphPET: A Prospective Clinical Study.
Journal: Annals of surgical oncology
Published: March 30, 2026
Precision neoadjuvant treatment with AI-assisted subtyping in HR+/HER2-breast cancer: A randomized, phase 2 trial FASCINATE-N.
Journal: Cell reports. Medicine
Published: February 04, 2026
Integrated genomic profiling identifies predictive biomarkers for neoadjuvant therapy response in Chinese breast cancer patients.
Journal: Cancer letters
Published: February 03, 2026
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: December 23, 2025
Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 25, 2025
On-treatment core needle biopsy identifies early responders for axillary surgery de-escalation: results from a prospective cohort.
Journal: British journal of cancer
Published: November 02, 2025
Omission of Axillary Surgery in Patients with Negative Axillary Evaluation Integrated with LymphPET: A Prospective Clinical Study.
Journal: Annals of surgical oncology
Published: October 30, 2025
Efficacy of Xueshuantong Injection in Reducing Residual Inflammatory Risk in Unstable Angina Patients: A Randomized Double-Blind Controlled Trial.
Journal: Chinese journal of integrative medicine
Published: July 11, 2025
CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 14, 2025
Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).
Journal: Molecular cancer
Published: April 28, 2025
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.
Journal: Cancer cell
Published: March 08, 2025
Bisphosphate nucleotidase 1 promotes progression and docetaxel resistance in triple-negative breast cancer via STUB1-mediated destabilization of LIMA1.
Journal: Cell death & disease
Published: February 28, 2025
Last Updated: 09/26/2026